This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HCA Healthcare Up 11% Since Q2, Will the Rally Continue?
by Zacks Equity Research
HCA Healthcare's (HCA) shares rallied led by strong second-quarter results.
Teladoc (TDOC) Up 26% in 22 Days, Will Upside Continue?
by Zacks Equity Research
Teladoc (TDOC) shares gain on strong operating performance in second quarter.
VIX Plunges to 7-Month Low: 5 Top-Ranked Momentum Picks
by Nalak Das
Since stock market performance and volatility index move in opposite directions, this is an extremely positive sign for the U.S. stocks.
Why Teladoc (TDOC) Stock Has More Than Doubled in a Year
by Zacks Equity Research
Teladoc (TDOC) continues to gain from high demand for its telehealth services.
4 Health Care Stocks Set to Beat Earnings Estimates in 4Q
by Zacks Equity Research
This attractive sector has several companies with upside potential.
Zacks.com featured expert Kevin Matras highlights: M.D.C., Ruth???s Hospitality, Medpace and Xylem
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: M.D.C., Ruth???s Hospitality, Medpace and Xylem
Winning Stock Picks from the Top 4 Industries with the Biggest Job Growth
by Kevin Matras
Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include MDC, RUTH, MEDP and XYL.
Will Higher Membership, Revenues Aid Cigna (CI) Q4 Earnings?
by Zacks Equity Research
Cigna's (CI) Q4 earnings should likely be aided by higher revenues from its healthcare, global supplement units, partly offset by Medicare membership loss.
DaVita (DVA) Partners with Epic to Launch EHR for Patients
by Zacks Equity Research
DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.
New Strong Buy Stocks for December 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?
by Zacks Equity Research
The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter
Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.
Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.
Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?
by Zacks Equity Research
Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.
Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.
PAREXEL's Acquisition by Pamplona Approved by Shareholders
by Zacks Equity Research
The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.
4 Momentum Stocks to Pick Despite MedTech Policy Debacle
by Zacks Equity Research
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Teladoc (TDOC) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
HCA Healthcare Rides on Acquisitions, Weak Volumes Bother
by Zacks Equity Research
A number of acquisitions have added facilities and widened network at HCA Healthcare (HCA). Weak admissions, however, continue to bother.
Healthcare Q2 Earnings Set to Release on Jul 31: HLS, MEDP
by Zacks Equity Research
The Healthcare sector's earnings will be driven by continued efforts by the players to provide high-quality, cost-effective care, partly offset by rising medical and operating costs.
What Falling Estimates & Price Mean for Medpace Holdings (MEDP)
by Zacks Equity Research
Medpace Holdings, Inc. (MEDP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Healthcare Q1 Earnings to Watch on May 1: THC, MEDP, CYH
by Zacks Equity Research
So far, 33.3% of the total Medical sector companies have reported first-quarter results.